Probi AB (publ) (PBBIF) Research

Probi AB (publ) is a Swedish entity specializing in the discovery, development, production, marketing, and distribution of probiotic solutions, which it supplies to clients across the health, pharmaceutical, and food sectors. The company conducts extensive research, with a primary focus on gut health, digestive well-being, immune system function, bone density, and efficient iron absorption, as well as addressing specific health needs for children, women, and the elderly. Its diverse product range includes both dietary supplements and various food and beverage items. These are available in numerous formats, such as capsules, tablets (including chewable and spherical types), powders, and an assortment of liquid options like fruit drinks, shots, carbonated beverages, and recovery drinks. Probi's market presence spans approximately 40 countries worldwide. The firm engages in significant academic collaborations, notably partnering with Örebro University for research into innovative needle-free vaccines and with La Trobe University to conduct a clinical trial examining the impact of Probi Osteo on Australian women. Founded in 1991 and headquartered in Lund, Sweden, Probi AB (publ) operates as a subsidiary of Symrise AG.

Open Probi AB (publ) (PBBIF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.